Inicio › Cáncer de pulmón de células no pequeñas › Illinois › Bloomington
Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Bloomington, IL
11 estudios para Cáncer de pulmón de células no pequeñas buscan participantes en centros de Bloomington y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutandoFase 3
- Illinois CancerCare-Bloomington, Bloomington
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ReclutandoFase 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · A 2 mi de distancia
- Carle Cancer Institute Normal, Normal · A 2 mi de distancia
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
ReclutandoFase 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ReclutandoFase 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
ReclutandoFase 2
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
ReclutandoFase 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutandoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · A 2 mi de distancia
- Carle Cancer Institute Normal, Normal · A 2 mi de distancia
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Illinois CancerCare-Bloomington, Bloomington
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ReclutandoEstudio observacional
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · A 2 mi de distancia
Ensayos de Cáncer de pulmón de células no pequeñas en otras ciudades
- Houston, TX145 estudios
- New York City, NY120 estudios
- Arlington, VA104 estudios
- Nashville, TN96 estudios
- Boston, MA89 estudios
- Los Angeles, CA87 estudios
- St. Louis, MO71 estudios
- Chicago, IL61 estudios
- Baltimore, MD60 estudios
- San Antonio, TX59 estudios
- Columbus, OH55 estudios
- Washington, DC54 estudios
Otros estudios en Bloomington
- Cáncer de pulmón9 estudios
- Cáncer de próstata7 estudios
- Cáncer del colon y del recto7 estudios
- Carcinoma de células escamosas de cabeza y cuello6 estudios
- Cáncer de seno5 estudios
- Cáncer de páncreas5 estudios
- Melanoma5 estudios
- Cáncer hipofaríngeo5 estudios
- Cáncer de laringe5 estudios
- Cáncer oral5 estudios
- Leucemia mielógena aguda4 estudios
- Cáncer de riñón (carcinoma de células renales)4 estudios
De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.